Literature DB >> 23895823

Interpreting changes in quality of life in atrial fibrillation: how much change is meaningful?

Paul Dorian1, Caroline Burk, Christopher M Mullin, Rosemary Bubien, Donna Godejohn, Matthew R Reynolds, Dhanunjaya R Lakkireddy, Alan P Wimmer, Anil Bhandari, John Spertus.   

Abstract

BACKGROUND: The Atrial Fibrillation Effect on QualiTy of Life (AFEQT) questionnaire is a novel quality of life (QOL) measure previously shown to be valid, reliable, and sensitive to clinical change in patients with atrial fibrillation (AF). The clinical relevance of a given change in the score is not known. The most useful "anchor" for a measure of meaningful change in QOL is patient-reported magnitude of change.
OBJECTIVE: The aim of this study was to define the interpretability of changes in the AFEQT score from the patients' perspective.
METHODS: With the use of the original validation study of AFEQT, in which 210 patients completed the questionnaire at baseline and at 3 months, we estimated the AFEQT score corresponding to a meaningful improvement in QOL using the patients' assessments of global change in QOL, AF symptoms from the Atrial Fibrillation Severity Scale (AFSS), and physicians' assessment of global QOL over the 3 months, as anchors.
RESULTS: In patients with a moderate improvement in global QOL, the AFEQT scores increased from 51.9 ± 21.8 to 70.8 ± 17.4 (an increase of 18.9 ± 20.7), compared with an increase of 6.9 ± 16.9 units in patients with "unimportant change" in global QOL. Physicians' global assessment yielded a similar change in AFEQT score corresponding to a moderate change in global QOL (21.3 ± 20.2 units). Patients with moderate improvement in AF symptom severity using the AFSS scale had an increase of 17.9 ± 11.8 units on the AFEQT scale. A change in 19 units in the AFEQT score corresponded to a 0.9 SD unit change or greater than a minimal important difference from a distribution based method.
CONCLUSIONS: A meaningful improvement in QOL in patients with AF can be measured from a change in the AFEQT score. These results can assist in monitoring patient progress and interpreting the effects of interventions in patients with AF.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23895823     DOI: 10.1016/j.ahj.2013.04.015

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  22 in total

1.  Atrial fibrillation symptom profiles associated with healthcare utilization: A latent class regression analysis.

Authors:  Megan M Streur; Sarah J Ratcliffe; David J Callans; M Benjamin Shoemaker; Barbara J Riegel
Journal:  Pacing Clin Electrophysiol       Date:  2018-05-15       Impact factor: 1.976

2.  Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF.

Authors:  Benjamin A Steinberg; DaJuanicia N Holmes; Karen Pieper; Larry A Allen; Paul S Chan; Michael D Ezekowitz; James V Freeman; Gregg C Fonarow; Bernard J Gersh; Elaine M Hylek; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; James Reiffel; Daniel E Singer; Eric D Peterson; Jonathan P Piccini
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-04-16

3.  The Atrial Fibrillation Therapies after ER visit: Outpatient Care for Patients with Acute AF - The AFTER3 Study.

Authors:  Paul Angaran; Zara Mariano; Vlad Dragan; Lily Zou; Clare L Atzema; Iqwal Mangat; Paul Dorian
Journal:  J Atr Fibrillation       Date:  2015-02-28

4.  The Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire: cultural adaptation and validation of the Greek version.

Authors:  P Tailachidis; Z Tsimtsiou; P Galanis; M Theodorou; D Kouvelas; K Athanasakis
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

5.  Atrial fibrillation symptom clusters and associated clinical characteristics and outcomes: A cross-sectional secondary data analysis.

Authors:  Megan Streur; Sarah J Ratcliffe; David Callans; M Benjamin Shoemaker; Barbara Riegel
Journal:  Eur J Cardiovasc Nurs       Date:  2018-05-22       Impact factor: 3.908

6.  Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE.

Authors:  Richard Schilling; Gurpreet Singh Dhillon; Claudio Tondo; Stefania Riva; Massimo Grimaldi; Federico Quadrini; Petr Neuzil; Gian-Battista Chierchia; Carlo de Asmundis; Ahmed Abdelaal; Liesbeth Vanderlinden; Tiffany Tan; Wern Yew Ding; Dhiraj Gupta; Vivek Y Reddy
Journal:  Europace       Date:  2021-06-07       Impact factor: 5.214

7.  Differences in Quality of Life Between Atrial Fibrillation Patients with Low Stroke Risk Treated With and Without Catheter Ablation.

Authors:  Ying Bai; Rong Bai; Jia-Hui Wu; Ting Zhang; Nian Liu; Xu-Bo Shi; Xin-Yao Liu; Xiao-Hui Liu; Xin Du; Jian-Zeng Dong; Chang-Sheng Ma
Journal:  J Am Heart Assoc       Date:  2015-09-16       Impact factor: 5.501

Review 8.  Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties.

Authors:  Dipak Kotecha; Amar Ahmed; Melanie Calvert; Mauro Lencioni; Caroline B Terwee; Deirdre A Lane
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

9.  Exploring Depressive Symptoms and Anxiety Among Patients With Atrial Fibrillation and/or Flutter at the Time of Cardioversion or Ablation.

Authors:  Theresa A Koleck; Shazia A Mitha; Angelo Biviano; Billy A Caceres; Elizabeth J Corwin; Isaac Goldenthal; Ruth Masterson Creber; Meghan Reading Turchioe; Kathleen T Hickey; Suzanne Bakken
Journal:  J Cardiovasc Nurs       Date:  2021 Sep-Oct 01       Impact factor: 2.468

10.  Effect of catheter ablation on quality of life in patients with atrial fibrillation and its correlation with arrhythmia outcome.

Authors:  Daniel Raine; Philip Langley; Ewen Shepherd; Stephen Lord; Stephen Murray; Alan Murray; John P Bourke
Journal:  Open Heart       Date:  2015-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.